News
Peptide research updates, regulatory changes, and industry developments.
May 21, 2026
Retatrutide Hits 30.3% Average Weight Loss in TRIUMPH-1 Phase 3 Trial
Eli Lilly’s investigational triple agonist retatrutide produced 30.3% average weight loss at 104 weeks in the pivotal TRIUMPH-1 Phase 3 trial — comparable to bariatric surgery outcomes. Here’s the full breakdown of the topline data and what comes next.
Read more →May 17, 2026
ECO2026 Recap — Oral GLP-1 Data from Novo, Lilly, and Viking
The European Congress on Obesity (ECO2026) ran May 12-15 in Istanbul. Novo Nordisk, Eli Lilly, and Viking Therapeutics each presented new oral GLP-1 data — including a Wegovy pill sub-analysis showing 21.6% weight loss in early responders, Lilly’s maintenance trial results, and Viking’s Phase 2 VK2735 readout. Here’s what the data showed and why it matters.
Read more →May 11, 2026
Retatrutide Phase 3 Update — Diabetes and Osteoarthritis Trials Hit Primary Endpoints
The first Phase 3 readouts from retatrutide’s TRIUMPH and TRANSCEND-T2D programs are in. Here’s what TRANSCEND-T2D-1 and TRIUMPH-4 showed and what comes next.
Read more →April 28, 2026
FDA Releases Official Agenda for July Peptide Compounding Meeting — Here’s What’s on It
The FDA published the official Federal Register notice for its July 23-24 Pharmacy Compounding Advisory Committee meeting, naming the seven peptides under review and the conditions each is being considered for.
Read more →April 16, 2026
FDA Moves to Restore Peptide Access — What Researchers Need to Know
The FDA posted a Federal Register notice considering lifting restrictions on seven Category 2 peptides, with an advisory panel scheduled for late July 2026. Here’s what it means for the research community.
Read more →April 12, 2026
RFK’s Peptide Ruling: Where Things Stand in April 2026
RFK Jr. announced 14 peptides would return to legal compounding status — but the FDA hasn’t published the official list yet. Here’s what we know, what’s still pending, and what it means for researchers.
Read more →April 10, 2026
RFK Jr. Announces 14 Peptides Coming Off FDA Restricted List
HHS Secretary Robert F. Kennedy Jr. announced that 14 of 19 previously restricted peptides will be moved off the FDA’s “do not compound” list — the largest regulatory reversal in U.S. peptide history.
Read more →